Dutton Associates announced today that it has updated its coverage of Pressure BioSciences and that it is reiterating its “Strong Speculative Buy” Rating and $10.00 Price Target. Dutton’s Senior Analyst, Mr. Denise T. Resnik, M.S., completed the 17-page report.

The research firm stated, “We are reiterating our rating of Pressure BioSciences Inc. as a Strong Speculative Buy and our 12-month price target of $10.00 per share. The Company has developed a unique and superior technology for the preparation of biological laboratory samples and is in the early stages of commercialization of its product platform. We expect that the shares will begin to reflect the substantial profits that we believe the Company can generate beginning in 2010.”

Dutton Associates continued to say, “We believe that as the coming 12-month period progresses, Pressure BioSciences will begin to demonstrate its ability to place a rapidly-increasing number of Barocyclers, and that the potential for substantial profits beginning in 2010 will begin to be recognized in these shares. Accordingly, we have established a 12-month price target of $10. Based on a 20 multiple of projected 2010 earnings per share of $1.51, a substantially higher 12-month target stock price could be generated even if this future value is discounted at a rate that reflects the risks to our projections.”

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board